Biotech Values

[iandy]

PRAN today:

Stock Market & Financial Investment News

News Breaks

January 30, 2014
10:50 EDT PRAN, PRAN Summer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Prana Biotechnology's PBT2 for treatment of Alzheimer and Huntington disease on an Analyst/Industry conference call to be held on January 30 at 11 am.

January 30, 2014
10:59 EDT PRAN Prana strength attrbuted to a positive recommendatoin by Navellier
Subscribe for More Information

09:46 EDT PRAN Summer Street's chief scientific officer holds analyst/industry conference call

------------------------------------------------------------------
I now own half of my second position in PRAN. The first position was highly profitable in a very short time. This stock has been very good to me. Every time it approaches my next target price the stock accelerates and I end up selling higher. The action looks more like accumulation than speculation.
I plan on holding onto a few thousand shares. As summer speculated, the PBT2 HD trial could have positive data on one or two targets and the stock could continue appreciating on apparent great news. Of course it would be even better if the drug actually works. In any event I am enjoying my time with PRAN so far.

Andy